PCRC_U18007

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue.

This phase III trial studies how well bupropion works in reducing cancer related fatigue in stage I-III breast cancer survivors. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. Cancer and its treatment can cause fatigue. Giving bupropion may improve cancer related fatigue in breast cancer survivors.

Key Eligibility:
• Been diagnosed with stage I-III breast cancer.
• Be currently breast cancer-free.
• Report moderate to severe fatigue in the past week.
• Attribute their fatigue to cancer and/or its treatment.
• Have completed surgery, radiation, standard dose chemotherapy, and/or targeted therapy 12-60 months previously (participants can be receiving hormonal therapy i.e., tamoxifen, anastrozole, letrozole, exemestane).
Phase III
NCT03996265
Cancer
Breast
Alison Conlin, M.D.
URCC NCORP Research Base
Amy Greathouse

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.